NEWS

Go back

Go to

ARCHIMED Impact Report 2021 – Investing for Better Healthcare: a Global Challenge

 October

 4, 

2022

At ARCHIMED, we are convinced of the crucial role healthcare companies play in sustaining humanity’s well-being, and we have witnessed for over 20 years their tremendous contribution.

We firmly believe that the healthcare industry has all the required characteristics to embody an impact vision: products and services with a greater purpose for human and animal health ; as we also believe that only companies realizing their sustainability potential can endure and create long-term value.

As an impact investor, we intend to guide healthcare actors towards building resilient and equitable healthcare systems, supporting access to a healthy life. To achieve this mission, we fully integrate sustainability throughout our activities involving all our teams and our portfolio companies.

To retrieve our ARCHIMED Impact Report 2021, please click here

About ARCHIMED

archimed.group

With offices in the US and Europe, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to North American and European healthcare businesses.
Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services.
ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ARCHIMED’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ARCHIMED manages €5 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ARCHIMED Press Contacts

France: Stéphanie du Ché
stephanie.duche@archimed.group
+33 (0)6 16 36 11 08

International: David Lanchner
dlanchner@lanchner.com,
+33 (0)6 33 43 50 76